title: [Tissue concentration of intravesically instilled (2"R)-4'-o-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer].
abstract: Twenty-one patients with superficial bladder cancer entered an analysis of single dose (2'R)-4'-O-tetrahydropyranyladriamycin (THP) or adriamycin (ADM) administration. The patients in each group that have been or not have been treated previously with anti-cancer drugs were randomized into two groups, one was given THP and the other ADM. Thirty-mg of THP or ADM dissolved in 30 ml of physiologic saline was instilled into the bladder, and retained for 1 hour. After 1 hour retention of the drugs, tumor tissues and normal mucosas were removed by punch biopsy forceps transurethrally. The tissue concentrations of THP and ADM were estimated by high performance liquid chromatography. The tissue concentrations of THP and ADM in the tumors were significantly greater (p < 0.05) than those in the normal bladder mucosas. The tissue concentration of THP in the tumors were greater than that of ADM. The tissue concentrations of THP and ADM in the tumor of patients who have been treated with anti-cancer drugs previously were less than those of patients who have not. This results demonstrated that prior therapy with anti-cancer drug may cause a resistance for intravesical instillation chemotherapy. However in patients with prior therapy, the tissue concentration of THP in the tumors were greater than that of ADM. Based on these findings, THP has been shown to be were effective as an intravesical instillating agent especially, in cases with prior chemotherapy.
authors.affiliation: Department of Urology, Okayama University Medical School.
authors.forename: T
authors.initials: T
authors.lastname: Saika
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: Y
authors.initials: Y
authors.lastname: Nasu
authors.forename: M
authors.initials: M
authors.lastname: Noda
authors.forename: N
authors.initials: N
authors.lastname: Akebi
authors.forename: S
authors.initials: S
authors.lastname: Kaku
authors.forename: M
authors.initials: M
authors.lastname: Takamatsu
authors.forename: H
authors.initials: H
authors.lastname: Ohmori
authors.forename: S
authors.initials: S
authors.lastname: Uno
authors.forename: T
authors.initials: T
authors.lastname: Johsen
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C027260:pirarubicin